报价延迟最少15分钟:2026/04/21 23:58 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.4 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.90/-0.74
|
|
企业价值
1.19B
|
| 资产负债 |
|
每股账面净值
-0.16
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
4.48M
|
|
每股收益
0.07
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise andexperience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline ofearlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. |
